A leading obesity doctor has said a new trial of weight loss drugs Mounjaro and Wegovy may lead advertisers to reconsider their prices.

Two blockbuster weight-loss drugs just went head-to-head — and the results are stunning. In a major new trial, Mounjaro ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

Weight loss drugs and jabs have become more popular and a recent study looked at the effectiveness of two drugs ...

The findings come after reports of nasty side effects - including eye problems, infections and gastrointestinal disorders - ...

Mounjaro and Wegovy are two of the biggest names in the world of weight-loss drugs but it's been unclear which is more ...

The effects they have on your body and mind vary, as Wegovy flips one appetite switch in your brain, while Mounjaro flips two ...

Mounjaro, manufactured by US drugmaker, and Wegovy by Danish drugmaker Novo Nordisk, cause weight loss by suppressing the ...

Both the Mounjaro and Wegovy jabs used in the trial were found to be effective treatments for patients with obesity, but one ...

Eventually, it was proven that Mounjaro is more affective than Wegovy in terms of weight loss, with 32 per cent of ...

Both Wegovy and Mounjaro are given as weekly injections via pre-filled pens that can be self-administered into the upper arm, ...